Table 3

Markers of oxidative stress, inflammation, and NO metabolites of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT

T2DM-SCTT2DMSCTCONT
AOPP (µmol/L)122.9 ± 47.1**88.1 ± 32.693.6 ± 66.063.1 ± 20.3
MDA (µmol/L)37.3 ± 16.7*30.3 ± 16.026.8 ± 7.122.9 ± 11.5
Nitrotyrosine (µmol/L)1.8 ± 1.2***,1.1 ± 0.6‎0.8 ± 0.50.6 ± 0.5
AGEs (µg/mL)2.7 ± 1.0***,†††,###1.5 ± 0.9*,0.7 ± 0.80.5 ± 0.4
FRAP (µmol/L449.2 ± 144.4555.3 ± 127.6568.5 ± 243.3627.5 ± 269.0
sVCAM-1 (ng/mL)1,079.4 ± 657.2826.2 ± 179.1‎897.1 ± 309.3724.0 ± 178.8
IL-1β (ng/mL)7.2 ± 3.0***,†††,###3.8 ± 2.1*,1.9 ± 1.01.7 ± 0.9
NOx (µmol/L)17.8 ± 5.921.2 ± 11.023.4 ± 9.521.9 ± 4.4
  • Data are means ± SD.

  • *Different from CONT, P < 0.05.

  • **P < 0.01.

  • ***P < 0.001.

  • †Different from SCT, P < 0.05.

  • †††P < 0.001.

  • ###Different from T2DM, P < 0.001.